195 related articles for article (PubMed ID: 36624361)
1. Examining Endpoint Concordance in Clinical Trials and Real-World Clinical Practice to Advance Real-World Evidence Utilization.
Schaumberg D; Larholt K; Apgar E; Pashos CL; Hirsch G
Ther Innov Regul Sci; 2023 May; 57(3):472-475. PubMed ID: 36624361
[TBL] [Abstract][Full Text] [Related]
2. Using Bayesian Evidence Synthesis Methods to Incorporate Real-World Evidence in Surrogate Endpoint Evaluation.
Wheaton L; Papanikos A; Thomas A; Bujkiewicz S
Med Decis Making; 2023 Jul; 43(5):539-552. PubMed ID: 36998240
[TBL] [Abstract][Full Text] [Related]
3. Bridging the Gap Between RCTs and RWE Through Endpoint Selection.
LoCasale RJ; Pashos CL; Gutierrez B; Dreyer NA; Collins T; Calleja A; Seewald MJ; Plumb JM; Liwing J; Tepie MF; Khosla S
Ther Innov Regul Sci; 2021 Jan; 55(1):90-96. PubMed ID: 32632753
[TBL] [Abstract][Full Text] [Related]
4. The Case for Real-world Evidence in the Future of Clinical Research on Chronic Myeloid Leukemia.
Webster J; Smith BD
Clin Ther; 2019 Feb; 41(2):336-349. PubMed ID: 30709609
[TBL] [Abstract][Full Text] [Related]
5. Folic acid supplementation and malaria susceptibility and severity among people taking antifolate antimalarial drugs in endemic areas.
Crider K; Williams J; Qi YP; Gutman J; Yeung L; Mai C; Finkelstain J; Mehta S; Pons-Duran C; Menéndez C; Moraleda C; Rogers L; Daniels K; Green P
Cochrane Database Syst Rev; 2022 Feb; 2(2022):. PubMed ID: 36321557
[TBL] [Abstract][Full Text] [Related]
6. Emulating Randomized Clinical Trials With Nonrandomized Real-World Evidence Studies: First Results From the RCT DUPLICATE Initiative.
Franklin JM; Patorno E; Desai RJ; Glynn RJ; Martin D; Quinto K; Pawar A; Bessette LG; Lee H; Garry EM; Gautam N; Schneeweiss S
Circulation; 2021 Mar; 143(10):1002-1013. PubMed ID: 33327727
[TBL] [Abstract][Full Text] [Related]
7. Use of real-world evidence for oncology clinical decision making in emerging economies.
Petracci F; Ghai C; Pangilinan A; Suarez LA; Uehara R; Ghosn M
Future Oncol; 2021 Aug; 17(22):2951-2960. PubMed ID: 34044583
[TBL] [Abstract][Full Text] [Related]
8. Use of real-world evidence in regulatory decisions for rare diseases in the United States-Current status and future directions.
Wu J; Wang C; Toh S; Pisa FE; Bauer L
Pharmacoepidemiol Drug Saf; 2020 Oct; 29(10):1213-1218. PubMed ID: 32003065
[TBL] [Abstract][Full Text] [Related]
9. Replication of randomized clinical trial results using real-world data: paving the way for effectiveness decisions.
Sheffield KM; Dreyer NA; Murray JF; Faries DE; Klopchin MN
J Comp Eff Res; 2020 Oct; 9(15):1043-1050. PubMed ID: 32914653
[TBL] [Abstract][Full Text] [Related]
10. What types of real-world evidence studies do U.S. commercial health plans cite in their specialty drug coverage decisions?
Panzer AD; Margaretos NM; Lai RC; Enright DE; Chambers JD
Pharmacoepidemiol Drug Saf; 2020 Oct; 29(10):1307-1311. PubMed ID: 32212282
[TBL] [Abstract][Full Text] [Related]
11. Improving Transparency to Build Trust in Real-World Secondary Data Studies for Hypothesis Testing-Why, What, and How: Recommendations and a Road Map from the Real-World Evidence Transparency Initiative.
Orsini LS; Berger M; Crown W; Daniel G; Eichler HG; Goettsch W; Graff J; Guerino J; Jonsson P; Lederer NM; Monz B; Mullins CD; Schneeweiss S; Brunt DV; Wang SV; Willke RJ
Value Health; 2020 Sep; 23(9):1128-1136. PubMed ID: 32940229
[TBL] [Abstract][Full Text] [Related]
12. Translational hurdles with cannabis medicines.
Graham M; Lucas CJ; Schneider J; Martin JH; Hall W
Pharmacoepidemiol Drug Saf; 2020 Oct; 29(10):1325-1330. PubMed ID: 32281186
[TBL] [Abstract][Full Text] [Related]
13. The future of Cochrane Neonatal.
Soll RF; Ovelman C; McGuire W
Early Hum Dev; 2020 Nov; 150():105191. PubMed ID: 33036834
[TBL] [Abstract][Full Text] [Related]
14. The Expanding Role of Real-World Evidence Trials in Health Care Decision Making.
Klonoff DC
J Diabetes Sci Technol; 2020 Jan; 14(1):174-179. PubMed ID: 30841738
[TBL] [Abstract][Full Text] [Related]
15. The Use of Real-World Evidence and Data in Clinical Research and Postapproval Safety Studies.
Lamberti MJ; Kubick W; Awatin J; McCormick J; Carroll J; Getz K
Ther Innov Regul Sci; 2018 Nov; 52(6):778-783. PubMed ID: 29714579
[TBL] [Abstract][Full Text] [Related]
16. Trial designs using real-world data: The changing landscape of the regulatory approval process.
Baumfeld Andre E; Reynolds R; Caubel P; Azoulay L; Dreyer NA
Pharmacoepidemiol Drug Saf; 2020 Oct; 29(10):1201-1212. PubMed ID: 31823482
[TBL] [Abstract][Full Text] [Related]
17. Real world evidence (RWE) - a disruptive innovation or the quiet evolution of medical evidence generation?
Khosla S; White R; Medina J; Ouwens M; Emmas C; Koder T; Male G; Leonard S
F1000Res; 2018; 7():111. PubMed ID: 30026923
[TBL] [Abstract][Full Text] [Related]
18. Use of Real-World Evidence to Drive Drug Development Strategy and Inform Clinical Trial Design.
Dagenais S; Russo L; Madsen A; Webster J; Becnel L
Clin Pharmacol Ther; 2022 Jan; 111(1):77-89. PubMed ID: 34839524
[TBL] [Abstract][Full Text] [Related]
19. Developing a framework to incorporate real-world evidence in cancer drug funding decisions: the Canadian Real-world Evidence for Value of Cancer Drugs (CanREValue) collaboration.
Chan K; Nam S; Evans B; de Oliveira C; Chambers A; Gavura S; Hoch J; Mercer RE; Dai WF; Beca J; Tadrous M; Isaranuwatchai W
BMJ Open; 2020 Jan; 10(1):e032884. PubMed ID: 31915169
[TBL] [Abstract][Full Text] [Related]
20. Conducting Real-world Evidence Studies on the Clinical Outcomes of Diabetes Treatments.
Schneeweiss S; Patorno E
Endocr Rev; 2021 Sep; 42(5):658-690. PubMed ID: 33710268
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]